Search research articles
Contact Us
Filters
Showing results (931-940 of 1,023) with videos related to
Page
of 103
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 29, 2012
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck
Jonas A de Souza, Darren W Davis, Yujian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Cabozantinib in progressive medullary thyroid cancer
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
The Lancet. Oncology
|
May 14, 2021
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G Sacco, Ruifeng Chen, Francis P Worden, et al.
JAMA Oncology
|
May 1, 2018
Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster
Ola Landgren, Rachel Zeig-Owens, Orsolya Giricz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
V M Villaflor, J M Melotek, T G Karrison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Y Guo, M-J Ahn, A Chan, et al.
Science (New York, N.Y.)
|
March 26, 2021
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, et al.
Journal of Oncology Practice
|
May 2, 2012
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center
Kim-Son H Nguyen, Rachel A Sanford, Mark S Huberman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2023
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
A J Rosenberg, C-Y Liao, T Karrison, et al.
Page
of 103
Search research articles
Search
Showing results (931-940 of 1,023) with videos related to
Sort By:
Page
of 103
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 29, 2012
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck
Jonas A de Souza, Darren W Davis, Yujian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Cabozantinib in progressive medullary thyroid cancer
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
The Lancet. Oncology
|
May 14, 2021
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G Sacco, Ruifeng Chen, Francis P Worden, et al.
JAMA Oncology
|
May 1, 2018
Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster
Ola Landgren, Rachel Zeig-Owens, Orsolya Giricz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
V M Villaflor, J M Melotek, T G Karrison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Y Guo, M-J Ahn, A Chan, et al.
Science (New York, N.Y.)
|
March 26, 2021
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, et al.
Journal of Oncology Practice
|
May 2, 2012
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center
Kim-Son H Nguyen, Rachel A Sanford, Mark S Huberman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2023
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
A J Rosenberg, C-Y Liao, T Karrison, et al.
Page
of 103